19 January 2017 - A major competitor to EpiPen, the lifesaving allergy injection that has become the latest flashpoint in the debate over high drug prices, will launch on Feb. 14 at a cash price of $360 for a two-pack, the company Kaléo announced on Thursday.

The announcement comes months after pharmaceutical company Mylan catapulted into politicians' crosshairs for hiking the price of EpiPen for years. Mylan has enjoyed a near monopoly on the growing allergy injection market, raising EpiPen's list price to $609 for a two-pack. Chief executive Heather Bresch was called to testify at a Congressional hearing last year, following another pharmaceutical executive who engaged in a massive price hike, Martin Shkreli.

Mylan has faced competition before, including from the Auvi-Q before it was recalled from the market. But EpiPen has been able to dominate the epinephrine auto-injector space because of its familiarity to patients and doctors, as well as various issues with its competitors.

Read Washington Post article